Journal of Clinical & Experimental Pharmacology

Bioavailability Study on Ciprofloxacin Tablet Formulation

Drump Unel^* Department of Environmental Sciences, Debre Tabor University, Debre Tabor, Ethiopia
^*Correspondence: Drump Unel, Department of Environmental Sciences, Debre Tabor University, Debre Tabor, Ethiopia, Email:

Received: 02-Mar-2023, Manuscript No. CPECR-23-21015; Editor assigned: 07-Mar-2023, Pre QC No. CPECR-23-21015 (PQ); Reviewed: 23-Mar-2023, QC No. CPECR-23-21015; Revised: 31-Mar-2023, Manuscript No. CPECR-23-21015 (R); Published: 07-Apr-2023, DOI: 10.35248/2161-1459.23.13.363

Description

Ciprofloxacin is an antibiotic that treats bacterial infections such as urinary tract infections, lung infections, and skin infections. It belongs to the fluoroquinolone antibiotic class and operates by suppressing bacterial growth and reproduction. Ciprofloxacin comes in a variety of forms, including oral pills, intravenous injections, and ear and ocular drops. They shall analyses the bioavailability of four distinct ciprofloxacin tablet brands in this post.

The amount of an active substance that reaches the systemic circulation and the rate at which it does so are referred to as bioavailability. Bioavailability of orally taken medications like ciprofloxacin is regulated by various factors, including drug formulation, the presence of food in the stomach, and individual variability in drug metabolism. Pharmacokinetic studies that assess the concentration of the drug in the bloodstream over time can be used to assess bioavailability.

Ciplox, Ciproflox, Cifran, and Ciprobid are the four ciprofloxacin tablet brands they shall compare in this study. These brands are manufactured by different companies and may differ in formulation, manufacturing process, and excipients. The bioavailability of four ciprofloxacin tablet brands was examined in a randomised crossover study on healthy volunteers. In a crossover design, 12 healthy male volunteers were randomly randomised to receive a single dose of each of the four brands of ciprofloxacin tablets. Blood samples were taken at predefined intervals following drug delivery, and the concentration of ciprofloxacin in the bloodstream was assessed [1-5].

The study's findings revealed that the bioavailability of the four ciprofloxacin tablet brands did not differ considerably. The area under the concentration-time curve of ciprofloxacin, which measures the amount of medication in the systemic circulation, was identical across all four brands. Ciprofloxacin's peak concentration in the bloodstream was also comparable across all four brands. According to these findings, the four ciprofloxacin tablet brands have similar pharmacokinetic profiles and are expected to be equally efficient in treating bacterial infections. It is crucial to note, however, that the study was conducted on healthy volunteers and may not reflect ciprofloxacin bioavailability in patients with illnesses [6-8].

When comparing ciprofloxacin tablet brands, another issue to examine is the presence of excipients, which are inert substances added to the formulation to improve drug stability, flavor, or appearance. Excipients can interfere with drug absorption and produce unpleasant effects in some people.

One of the anti-infective agents that have received extensive attention is resistance to antibacterial medications, particularly quinolones. For example, one study discovered that the use of quinolones, like in most prior studies, dramatically boosted the resistance of isolated E. coli from people with Urinary Tract Infections (UTI). Ciprofloxacin, a fluoroquinolone of the second generation, is one of the most commonly used quinolones. It has a broad spectrum of anti-infective activity and is efficiently absorbed from the Gastro Intestinal (GI) tract, with an absolute bioavailability of 70% to 85% following oral dosing.

It is an alternative for treating gastrointestinal, skin, and bone infections, complicated urinary tract infections, sexually transmitted infections, and lower respiratory tract infections, among other infections, because it is widely distributed throughout the body and tissue concentrations are frequently higher than serum concentrations. Ciprofloxacin, a quinolone antibiotic, was found to be ineffective in treating Salmonella enterica serotype Paratyphi A-induced enteric fever in Kuwait.

In medical practice, selecting the finest ciprofloxacin brand from among the others is critical for attaining the most cost-effectiveness benefit [9,10]. Although a few studies in Nigeria have been conducted using certain ciprofloxacins available on the Nigerian market to address this issue, almost all of these research used an in vitro assessment technique, which may not be a process that occurs in vivo.

References

1. Billingsley ML. Druggable targets and targeted drugs: Enhancing the development of new therapeutics. Pharmacology. 2008; 82(4):239-244.

   [Crossref] [Google Scholar] [PubMed]

2. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol. 2006; 16(1):127-136.

   [Crossref] [Google Scholar] [PubMed]

3. Defining the role of pharmacology in the emerging world of translational research. 2009

   [Google Scholar]

4. Kenakin T, Williams M. Defining and characterizing drug/compound function. Biochem Pharmacol. 2014; 87(1):40-63.

   [Crossref] [Google Scholar] [PubMed]

5. Gabrielsson J, Green AR. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther. 2009; 331(3):767-774.

   [Crossref] [Google Scholar] [PubMed]

6. Lees P, Giraudel J, Landoni MF, Toutain PL. PK–PD integration and PK–PD modelling of nonsteroidal anti‐inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther. 2004; 27(6):491-502.

   [Crossref] [Google Scholar] [PubMed]

7. Toutain PL, Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. J Vet Pharmacol Ther. 2004; 27(6):467-477.

   [Crossref] [Google Scholar] [PubMed]

8. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther. 1997; 35(10):401-413.

   [Google Scholar] [PubMed]

9. Bulitta JB, Ly NS, Yang JC. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53(1):46-56.

   [Crossref] [Google Scholar] [PubMed]

10. Janssen A, Bennis FC, Mathôt RA. Adoption of machine learning in pharmacometrics: An overview of recent implementations and their considerations. Pharmaceutics. 2022; 14(9): 1814.

    [Crossref] [Google Scholar] [PubMed]